A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

This trial is testing HLX43 — a new antibody-drug conjugate (a drug that delivers chemotherapy directly to cancer cells via an antibody) that targets PD-L1 — in patients with advanced esophageal squamous cell carcinoma (ESCC) whose cancer has progressed after standard treatment. **You may be eligible if...** - You have been diagnosed with esophageal squamous cell carcinoma confirmed by biopsy or pathology - Your cancer is advanced and has failed or you could not tolerate prior first-line treatment (including platinum-based chemo and immunotherapy if your tumor is PD-L1 positive) - You are between 18 and 75 years old - Your general health is adequate to handle this treatment **You may NOT be eligible if...** - You have already received too many prior lines of treatment beyond the study criteria - Your overall health or organ function is too poor - You have uncontrolled brain metastases or active autoimmune conditions - You have had severe prior reactions to similar types of antibody-drug therapy Talk to your doctor to see if this trial is right for you.